Shan Lin, PhD

Shan  Lin, PhD

Academic Title: Assistant Professor

Research Center: Ben Towne Center for Childhood Cancer Research

"It is amazing to see many clinical transformations are initiated from laboratory research. I am fascinated in the molecular mechanisms governing the leukemia development and leukemia vulnerabilities. I am enthusiastic about translating our discoveries into therapeutic strategies to help patients and their families in combating cancer. "

  • Biography

    Dr. Shan Lin received his PhD degree in molecular and developmental biology at the University of Cincinnati, where he focused on using human hematopoietic stem and progenitor cells to model the pathogenesis of acute leukemia driven by fusion proteins and characterizing critical pathways contributing to leukemia development. During his postdoctoral training at the Dana-Farber Cancer Institute, he applied functional genomic approaches, including an in vivo CRISPR screen pipeline, to identify the novel targets of acute myeloid leukemia (AML), and to discover the synergistic targets that enhance the efficacy of apoptosis-stimulating agents against AML. He joined the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute in 2023. The research interests of his lab include investigating the molecular mechanisms of programmed cell death regulation in leukemia and harnessing this knowledge to advance the treatment of difficult-to-treat hematologic malignancies.

    • Related Pages

    • Lin Lab

      Our research goals are to expand the knowledge domain of programmed cell death and leverage it in treating acute myeloid leukemia (AML) and other hematological malignancies.

  • Awards and Honors
    Award Name Award Description Awarded By Award Date
    K99 Pathway to Independence Award NIH/NCI
    LLS CDP Achievement Award Leukemia & Lymphoma Society
  • Publications

    Other Publications

    • Darabedian N, Ji W, Fan M, Lin S, Seo HS, Vinogradova EV, Yaron TM, Mills EL, Xiao H, Senkane K, Huntsman EM, Johnson JL, Che J, Cantley LC, Cravatt BF, Dhe-Paganon S, Stegmaier K, Zhang T, Gray NS, Chouchani ET
      Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor.
      36823351 Nature chemical biology, 2023 July : 19(7)815-824 PMCID:PMC10330000
    • Larrue C, Mouche S, Lin S, Simonetta F, Scheidegger NK, Poulain L, Birsen R, Sarry JE, Stegmaier K, Tamburini J
      Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.
      36739349 Leukemia, 2023 April : 37(4)765-775 PMCID:PMC10079528
    • Lu DY, Ellegast JM, Ross KN, Malone CF, Lin S, Mabe NW, Dharia NV, Meyer A, Conway A, Su AH, Selich-Anderson J, Taslim C, Byrum AK, Seong BKA, Adane B, Gray NS, Rivera MN, Lessnick SL, Stegmaier K
      The ETS transcription factor ETV6 constrains the transcriptional activity of EWS-FLI to promote Ewing sarcoma.
      36658220 Nature cell biology, 2023 Feb. : 25(2)285-297 PMCID:PMC9928584
    • Tirtakusuma R, Szoltysek K, Milne P, Grinev VV, Ptasinska A, Chin PS, Meyer C, Nakjang S, Hehir-Kwa JY, Williamson D, Cauchy P, Keane P, Assi SA, Ashtiani M, Kellaway SG, Imperato MR, Vogiatzi F, Schweighart EK, Lin S, Wunderlich M, Stutterheim J, Komkov A, Zerkalenkova E, Evans P, McNeill H, Elder A, Martinez-Soria N, Fordham SE, Shi Y, Russell LJ, Pal D, Smith A, Kingsbury Z, Becq J, Eckert C, Haas OA, Carey P, Bailey S, Skinner R, Miakova N, Collin M, Bigley V, Haniffa M, Marschalek R, Harrison CJ, Cargo CA, Schewe D, Olshanskaya Y, Thirman MJ, Cockerill PN, Mulloy JC, Blair HJ, Vormoor J, Allan JM, Bonifer C, Heidenreich O, Bomken S
      Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.
      35839448 Blood, 2022 Oct 27 : 140(17)1875-1890 PMCID:PMC10488321
    • Ellegast JM, Alexe G, Hamze A, Lin S, Uckelmann HJ, Rauch PJ, Pimkin M, Ross LS, Dharia NV, Robichaud AL, Conway AS, Khalid D, Perry JA, Wunderlich M, Benajiba L, Pikman Y, Nabet B, Gray NS, Orkin SH, Stegmaier K
      Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts.
      35405016 Cancer discovery, 2022 Jul 6 : 12(7)1760-1781 PMCID:PMC9308469
    • Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, Wechsler CS, Kugener G, Robichaud AL, Conway AS, Mashaka T, Mouche S, Adane B, Ryan JA, Mancias JD, Younger ST, Piccioni F, Lee LH, Wunderlich M, Letai A, Tamburini J, Stegmaier K
      An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.
      34531254 Cancer discovery, 2022 Feb. : 12(2)432-449 PMCID:PMC8831447
    • Seong BKA, Dharia NV, Lin S, Donovan KA, Chong S, Robichaud A, Conway A, Hamze A, Ross L, Alexe G, Adane B, Nabet B, Ferguson FM, Stolte B, Wang EJ, Sun J, Darzacq X, Piccioni F, Gray NS, Fischer ES, Stegmaier K
      TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.
      34329586 Cancer cell, 2021 Sep 13 : 39(9)1262-1278.e7 PMCID:PMC8443273
    • Adane B, Alexe G, Seong BKA, Lu D, Hwang EE, Hnisz D, Lareau CA, Ross L, Lin S, Dela Cruz FS, Richardson M, Weintraub AS, Wang S, Iniguez AB, Dharia NV, Conway AS, Robichaud AL, Tanenbaum B, Krill-Burger JM, Vazquez F, Schenone M, Berman JN, Kung AL, Carr SA, Aryee MJ, Young RA, Crompton BD, Stegmaier K
      STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.
      34129824 Cancer cell, 2021 Jun 14 : 39(6)827-844.e10 PMCID:PMC8378827
    • Pikman Y, Tasian SK, Sulis ML, Stevenson K, Blonquist TM, Apsel Winger B, Cooper TM, Pauly M, Maloney KW, Burke MJ, Brown PA, Gossai N, McNeer JL, Shukla NN, Cole PD, Kahn JM, Chen J, Barth MJ, Magee JA, Gennarini L, Adhav AA, Clinton CM, Ocasio-Martinez N, Gotti G, Li Y, Lin S, Imamovic A, Tognon CE, Patel T, Faust HL, Contreras CF, Cremer A, Cortopassi WA, Garrido Ruiz D, Jacobson MP, Dharia NV, Su A, Robichaud AL, Saur Conway A, Tarlock K, Stieglitz E, Place AE, Puissant A, Hunger SP, Kim AS, Lindeman NI, Gore L, Janeway KA, Silverman LB, Tyner JW, Harris MH, Loh ML, Stegmaier K
      Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
      33563661 Cancer discovery, 2021 June : 11(6)1424-1439 PMCID:PMC8178162
    • Tarumoto Y, Lin S, Wang J, Milazzo JP, Xu Y, Lu B, Yang Z, Wei Y, Polyanskaya S, Wunderlich M, Gray NS, Stegmaier K, Vakoc CR
      Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo.
      31697837 Blood, 2020 Jan 2 : 135(1)56-70 PMCID:PMC6940199
    • Lin S, Ptasinska A, Chen X, Shrestha M, Assi SA, Chin PS, Imperato MR, Aronow BJ, Zhang J, Weirauch MT, Bonifer C, Mulloy JC
      A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
      28710059 Blood, 2017 Sep 7 : 130(10)1213-1222 PMCID:PMC5606002
    • Lin S, Luo RT, Shrestha M, Thirman MJ, Mulloy JC
      The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment.
      28637661 Blood, 2017 Aug 17 : 130(7)903-907 PMCID:PMC5561902
    • Lin S, Mulloy JC, Goyama S
      RUNX1-ETO Leukemia.
      28299657 Advances in experimental medicine and biology, 2017 : 962151-173
    • Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ
      Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
      27846391 Cancer cell, 2016 Nov 14 : 30(5)737-749
    • Link KA, Lin S, Shrestha M, Bowman M, Wunderlich M, Bloomfield CD, Huang G, Mulloy JC
      Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation.
      27457952 Proceedings of the National Academy of Sciences of the United States of America, 2016 Aug 9 : 113(32)9075-80 PMCID:PMC4987773
    • Tran NT, Su H, Khodadadi-Jamayran A, Lin S, Zhang L, Zhou D, Pawlik KM, Townes TM, Chen Y, Mulloy JC, Zhao X
      The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation.
      27118388 EMBO reports, 2016 June : 17(6)887-900 PMCID:PMC5278610
    • Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC
      The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
      22337712 Blood, 2012 Jul 26 : 120(4)709-19 PMCID:PMC3412344